#USA #Seoul #Seegene USA #Allplex PCR #FDA EUA

Advancing Diagnostic Precision in Viral Infections

In a groundbreaking development, Seegene USA has obtained Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its innovative Allplex™ HSV-1&2/VZV/MPXV assay. This multiplex real-time PCR assay is designed for the simultaneous detection and differentiation of four significant viral pathogens associated with ulcerative skin lesions: Herpes Simplex Virus types 1 and 2 (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), and Monkeypox Virus (MPXV).

Significance of the Assay

The unique design of this assay addresses a crucial gap in current diagnostic capabilities. While existing tests often focus on a single pathogen, the Allplex assay enables clinicians to test for multiple viruses at once. This is particularly beneficial as HSV-1, HSV-2, VZV, and MPXV commonly present with similar symptoms, including vesicular and pustular lesions.

Missed diagnoses can occur when clinicians only test for one virus at a time, potentially overlooking additional infections that contribute to the patient's symptoms. In a recent study presented at the 2024 Clinical Virology Symposium, 54 out of 966 samples that tested negative for single pathogens were later identified as positive for HSV, VZV, or MPXV using the multiplex method. This highlights the assay's potential for enhancing patient diagnosis and treatment accuracy.

Technology Behind the Assay

Developed using a suite of Seegene's high-multiplex PCR technologies, the assay incorporates advanced techniques such as Dual Priming Oligonucleotide (DPO™) and Multiple Detection Temperatures (MuDT™). Such innovations ensure high sensitivity and specificity, enabling comprehensive coverage of the target viruses in a single reaction.

Seegene has utilized an automated product development platform, known as the Seegene Digitalized Development System, to streamline the process, facilitating efficient product development without compromising on quality.

Company Vision and Future Prospects

According to Jun Kim, CEO of Seegene USA, the authorization of this multiplex assay signifies a significant advancement in addressing U.S. clinical laboratory needs. “This marks an important step in bringing our high-multiplex capabilities to the U.S. market, paving the way for developing locally relevant diagnostic products,” he stated.

Seegene intends to expand its portfolio of multiplex PCR assays to cater to the needs of U.S. healthcare providers actively. The company is also focused on enhancing its regional partnerships through its Technology-Sharing Initiative, which aims to foster local production and development of multiplex tests tailored to specific community health needs.

In a world still grappling with infectious diseases, Seegene stands ready to bolster preparedness for potential outbreaks by improving access to advanced diagnostics. This includes not just this assay but also additional innovations and tools in their diagnostic ecosystem, including real-time data analytics platforms and fully automated PCR systems designed to simplify workflow in molecular testing labs.

As these technologies continue to evolve, the implications for diagnostics in public health are vast. Seegene’s commitment to developing cutting-edge diagnostic solutions supports public health initiatives and significantly enhances the ability to respond effectively to viral outbreaks.

Conclusion

The Allplex™ HSV-1&2/VZV/MPXV assay marks a pivotal moment in the field of viral diagnostics. By expanding the capabilities of clinical laboratories, Seegene USA is positioned to improve the accuracy of diagnoses and, ultimately, patient care, setting a new standard in the fight against viral infections. This initiative demonstrates the importance of innovative thinking and technology in addressing critical healthcare challenges.